Biomarkers Market Research Report: Size, Share, Trend Analysis By Types (Predictive Biomarkers, Diagnostic Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers, Research Biomarkers), By Applications (Oncology, Cardiovascular, Neurology, Infectious Diseases, Autoimmune Diseases), By Technology (Omics Technologies, Imaging Technologies, Bioinformatics, Mass Spectrometry, PCR Technologies), By End-use (Pharmaceutical Companies, Clinical Laboratories, Research Institutions, Diagnostic Laboratories), and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035
Global Biomarkers Market Size was valued at USD 60.66 Billion in 2024 & the market is projected to grow from USD 66.68 Billion in 2025 to USD 171.69 Billion by 2035, registering a CAGR of 9.90% during the forecast period 2025–2035. North America led the market with over 45% share, generating around USD 27.3 Billion in revenue. Growing adoption of precision medicine is driving the Biomarker Market, as biomarkers enable early disease detection, patient stratification, treatment selection, and therapeutic monitoring. Expanding genomic research and biomarker-based diagnostics are accelerating personalized healthcare while improving clinical outcomes across multiple therapeutic areas. According to the WHO Data Portal, noncommunicable diseases account for 41 million deaths annually (74% of all global deaths), increasing demand for biomarker-based diagnostics that support earlier detection, precision treatment selection, and continuous disease monitoring.
The Biomarkers Market is experiencing robust growth driven by technological advancements and increasing demand for personalized medicine.
| 2024 Market Size | 60.66 (USD Billion) |
| 2035 Market Size | 171.69 (USD Billion) |
| CAGR (2025 - 2035) | 9.92% |
Companies such as Roche (CH), Thermo Fisher Scientific (US), Abbott Laboratories (US), Merck KGaA (DE), Agilent Technologies (US), Bio-Rad Laboratories (US), Illumina (US), Qiagen (DE), PerkinElmer (US) are some of the major participants in the global market.
Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry
The Biomarkers Market is currently experiencing a transformative phase, characterized by rapid advancements in technology and an increasing emphasis on personalized medicine. This evolution is driven by the growing recognition of biomarkers as essential tools for disease diagnosis, prognosis, and treatment monitoring. As healthcare systems worldwide strive for more efficient and effective patient care, the integration of biomarkers into clinical practice appears to be gaining momentum. Furthermore, the rise of precision medicine is likely to enhance the demand in the Biomarkers Market, as they enable tailored therapeutic approaches that align with individual patient profiles.
In addition to technological advancements, regulatory frameworks are evolving to accommodate the complexities associated with biomarker development and application. This shift may facilitate faster approvals and market entry for innovative biomarker tests, thereby expanding their accessibility to healthcare providers and patients alike. Moreover, collaborations between academic institutions, biotechnology firms, and pharmaceutical companies are becoming increasingly common, fostering an environment conducive to innovation. As the Biomarkers Market continues to mature, it seems poised for sustained growth, driven by ongoing research and development efforts aimed at uncovering new biomarkers and their potential applications in various therapeutic areas.
The Biomarkers Market is witnessing a notable increase in the adoption of companion diagnostics. These tests are designed to identify patients who are most likely to benefit from specific therapies, thereby enhancing treatment efficacy. This trend reflects a broader shift towards personalized medicine, where therapies are tailored to individual patient characteristics, potentially improving outcomes and minimizing adverse effects.
The integration of artificial intelligence (AI) into biomarker discovery and analysis is emerging as a significant trend. AI technologies are being utilized to process vast amounts of biological data, enabling researchers to identify novel biomarkers more efficiently. This advancement may lead to quicker insights and a deeper understanding of disease mechanisms, ultimately accelerating the development of targeted therapies.
The applications of biomarkers are expanding beyond traditional areas such as oncology. There is a growing interest in utilizing biomarkers for various conditions, including cardiovascular diseases, neurological disorders, and infectious diseases. This diversification suggests a broader recognition of the potential of biomarkers to enhance diagnostic accuracy and treatment strategies across multiple therapeutic domains.
Technological advancements in genomic sequencing and analysis are propelling the Biomarkers Market forward. Innovations such as next-generation sequencing (NGS) and CRISPR technology have revolutionized the way biomarkers are identified and utilized in clinical settings. These technologies enable researchers to analyze vast amounts of genetic data quickly and accurately, facilitating the discovery of novel biomarkers for various diseases. The integration of these advanced technologies is expected to enhance the efficiency of biomarker development processes, thereby reducing time-to-market for new diagnostic tests. As a result, the market is likely to witness substantial growth, with the genomic biomarker segment anticipated to account for a significant share of the overall market by 2025. This trend underscores the importance of continuous investment in research and development within the biomarker domain.
The shift towards personalized medicine is a significant driver of the Biomarkers Market. As healthcare evolves, there is an increasing recognition of the need for tailored treatment approaches that consider individual patient characteristics. Biomarkers serve as essential tools in this paradigm, enabling healthcare providers to select the most effective therapies based on a patient's unique biological profile. This trend is reflected in the rising number of biomarker-based companion diagnostics, which are designed to identify patients who are most likely to benefit from specific treatments. The market for personalized medicine is projected to grow substantially, with estimates suggesting it could reach over 2 trillion USD by 2025. This growth is likely to further stimulate the market, as the demand for innovative diagnostic solutions continues to rise.
The rising incidence of chronic diseases such as cancer, diabetes, and cardiovascular disorders is a primary driver of the Biomarkers Market. As these conditions become more prevalent, the demand for effective diagnostic tools and personalized treatment options intensifies. Biomarkers play a crucial role in early detection and monitoring of these diseases, thereby enhancing patient outcomes. According to recent estimates, the market for biomarkers is projected to reach approximately 60 billion USD by 2026, reflecting a compound annual growth rate of around 12%. This growth is largely attributed to the increasing focus on precision medicine, which relies heavily on biomarker identification and validation. Consequently, the market is expected to expand significantly as healthcare providers seek innovative solutions to manage chronic diseases.
Regulatory agencies are increasingly recognizing the importance of biomarkers in drug development and patient care, which is positively impacting the Biomarkers Market. Initiatives aimed at streamlining the approval process for biomarker-based diagnostics are being implemented, thereby encouraging innovation and investment in this field. For instance, the FDA has established guidelines for the development and validation of biomarkers, which facilitate their integration into clinical practice. This regulatory support not only enhances the credibility of biomarker applications but also fosters collaboration between industry stakeholders and regulatory bodies. As a result, the market is likely to experience accelerated growth, with more companies entering the market to develop novel biomarker solutions that meet regulatory standards.
Investment in research and development (R&D) within the biomarker sector is a crucial driver of the Biomarkers Market. Increased funding from both public and private sectors is enabling researchers to explore new biomarker candidates and develop innovative diagnostic tools. This influx of capital is particularly evident in the fields of oncology and rare diseases, where the need for effective biomarkers is paramount. According to recent reports, R&D spending in the biomarker space is expected to exceed 10 billion USD by 2025, reflecting a growing commitment to advancing biomarker science. This trend is likely to result in the discovery of novel biomarkers that can improve disease detection and treatment, thereby further propelling the market.
The market exhibits a diverse distribution among the different types of biomarkers. Predictive biomarkers currently hold the largest Biomarkers Market share of 39% within this segment, serving as essential tools in anticipating patient responses to therapeutic interventions. Following close behind, diagnostic biomarkers are emerging as a critical component in clinical settings, facilitating the identification of diseases at earlier stages.
Roche continues expanding predictive biomarker solutions through companion diagnostics supporting personalized oncology treatment selection and precision medicine development across global healthcare markets.
In the global Biomarkers Market, oncology holds the dominant share of 42% , driven by the increasing prevalence of cancer and advancements in diagnostic technologies. The segments of cardiovascular, neurology, infectious diseases, and autoimmune diseases also play significant roles; however, their market shares are comparatively smaller. The demand for targeted therapies and personalized medicine continues to enhance the role of biomarkers in guiding treatment decisions within oncology, placing it at the forefront of the market.
Thermo Fisher Scientific continues strengthening oncology biomarker capabilities through advanced genomic testing technologies supporting precision cancer diagnosis and targeted therapeutic development worldwide.
The market exhibits a diverse distribution of technology segments, with Omics Technologies holding the largest Biomarkers Market share of 46%. This segment encompasses genomics, proteomics, and metabolomics, playing a pivotal role in biomarker discovery and validation. In contrast, Bioinformatics is emerging as the fastest-growing segment, driven by the increasing need for data analysis in biomarker research. The integration of advanced computational tools in bioinformatics accelerates the analysis and interpretation of complex biological data generated through various omics approaches.
Omics Technologies: Dominant vs. Bioinformatics: Emerging
Omics Technologies is characterized by its comprehensive approaches to understanding biological processes at a molecular level, positioning it as the dominant segment in the market. This segment includes various technologies that facilitate the study of the genome, proteome, and metabolome, providing critical insights for biomarker identification. Conversely, Bioinformatics represents an emerging segment that leverages computational power to analyze vast datasets, driven by the need for precision medicine. Its growth is fueled by advancements in machine learning and data analytics, essential for translating omics data into actionable insights, making it instrumental in the future of biomarker research.
The end-use segment is significantly dominated by pharmaceutical companies, which hold a substantial 55% share due to their extensive research and development activities. These companies utilize biomarkers for drug discovery, development, and personalized medicine, thereby driving a large portion of the market. Conversely, clinical laboratories are emerging rapidly as a critical component of the market. Their role in the development and application of biomarkers in diagnostics and patient management is increasingly recognized, allowing them to capture a growing share in the sector.
Pharmaceutical Companies (Dominant) vs. Clinical Laboratories (Emerging)
Pharmaceutical companies are at the forefront of the Biomarkers Market, leveraging biomarkers to enhance drug efficacy and safety profiles through targeted therapies. Their investment in biopharmaceuticals and personalized medicine continues to grow, solidifying their dominant market position. On the other hand, clinical laboratories are becoming increasingly vital as the demand for precise diagnostics rises. They focus on rapidly integrating biomarker technologies into routine testing, which allows for real-time patient monitoring and treatment adjustments. The synergy between pharmaceutical advances and clinical laboratory capabilities positions them uniquely to meet the evolving healthcare landscape.
Get more detailed insights about Biomarker Market Request Free Sample
The Biomarkers Market experienced substantial growth across various regions. North America leads in the market Size, accounting for over 45% of the global revenue in 2024, reflecting its dominance in research and innovation.
Europe Biomarkers Market size was valued at USD 12.5 billion in 2024, making it the second-largest regional market with a 20.61% share, supported by advancements in healthcare and regulatory frameworks. The Asia Pacific region accounted for 7.5 USD Billion in 2024, growing to 15.0 USD Billion, driven by increasing healthcare expenditure and a rising population.
South America, with a market value of 2.5 USD Billion, is projected to grow to 5.0 USD Billion as healthcare access improves. The Middle East and Africa segment was valued at 2.0 USD Billion, expected to reach 3.7 USD Billion, influenced by growing awareness of personalized medicine.
These regional insights emphasized the market's segmentation and highlighted the opportunities for growth in different geographical areas, reflecting trends in healthcare advancements and the demand for innovative solutions.
The Biomarkers Market has evolved significantly over the last few years, driven by advancements in technology and increasing demand for personalized medicine. Competitive insights in this market reveal a landscape filled with collaboration, innovation, and strategic partnerships among key players. Companies are leveraging research and development to enhance their product offerings and maintain their competitive edge. The market is characterized by various segments based on types, applications, and countries, leading to diverse competition and strategic positioning. The emphasis on diagnostic solutions, drug development, and targeted therapies has stimulated growth, pushing major players to adopt aggressive marketing and distribution strategies tailored to different geographic regions. Novartis has established a substantial presence in the Biomarkers Market through its robust pipeline of biomarker development initiatives. The company focuses on integrating biomarkers into its drug discovery processes to enhance patient selection, improve treatment outcomes, and minimize adverse effects. The strengths of Novartis in this domain lie in its extensive research capabilities, collaborations with academic institutions and biotechnology firms, and a strong portfolio of innovative therapies. Novartis's commitment to advancing biomarker research underscores its role in developing precision medicine, amplifying its influence in the global healthcare landscape. Its strategic focus on rare diseases and oncology has positioned the company as a leader in utilizing biomarkers for therapeutic advancements, contributing significantly to its overall growth and market competitiveness. Thermo Fisher Scientific plays a crucial role in the Biomarkers Market, primarily known for its comprehensive range of analytical instruments, reagents, and consumables that support biomarker discovery and validation. The company’s significant strengths include its extensive product portfolio designed for biomarker research, including technologies for gene expression analysis, mass spectrometry, and next-generation sequencing. Thermo Fisher Scientific has made strategic moves through a series of mergers and acquisitions to expand its capabilities and enhance market presence globally. These integrations have allowed the company to offer integrated solutions that streamline biomarker research, thereby increasing efficiency and reliability in biopharmaceutical applications. Its commitment to innovation and customer support ensures Thermo Fisher Scientific remains a vital contributor to the evolving landscape of biomarkers, reinforcing its competitive stance within the industry on a global scale.
The Elecsys PRO-C3 test, created in partnership with Nordic Bioscience, was approved by the FDA in May 2025 by F. Hoffmann-La Roche Ltd. to evaluate the degree of liver fibrosis in patients with steatotic liver disease linked to metabolic dysfunction.
Roche also introduced the VENTANA MET (SP44) RxDx Assay in May 2025, which is intended to determine which patients with non-small cell lung cancer are suitable for targeted MET inhibitor treatments. By completing the purchase of SYNLAB's clinical diagnostics business in Spain in April 2025, Eurofins Scientific greatly increased its capacity for molecular diagnostics and biomarker validation.
Ignite Biomedical and Liquid Biosciences formed a strategic alliance in April 2025 to leverage AI-driven bioinformatics systems to find and verify new biomarkers for substance use disorders. Thermo Fisher Scientific and the UK Biobank Pharma proteome Project joined forces in January 2025 to fund the biggest proteome project in the world devoted to biomarker validation and development.
To enhance early identification and risk stratification in Alzheimer's disease, QIAGEN and Eli Lilly announced in September 2024 that they would be working together to create a QIAstat-Dx in vitro diagnostic panel for APOE genotyping.
The Biomarkers Industry size is projected to reach USD 27.3 Billion by 2035, growing at a CAGR of 9.92% , driven by advancements in personalized medicine, increased R&D investments, and rising demand for early disease detection.
New opportunities lie in:
By 2035, the Biomarkers Market is expected to achieve substantial growth, reflecting its critical role in healthcare innovation.
| MARKET SIZE 2024 | 60.66(USD Billion) |
| MARKET SIZE 2025 | 66.68(USD Billion) |
| MARKET SIZE 2035 | 171.69(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.92% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Roche (CH), Thermo Fisher Scientific (US), Abbott Laboratories (US), Merck KGaA (DE), Agilent Technologies (US), Bio-Rad Laboratories (US), Illumina (US), Qiagen (DE), PerkinElmer (US) |
| Segments Covered | Types, Applications, Technology, End-use, Regional |
| Key Market Opportunities | Advancements in personalized medicine drive demand for innovative biomarkers in diagnostics and therapeutics. |
| Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |
The Biomarkers Market is valued at approximately 60.66 USD Billion in 2024, and it is expected to grow significantly in the coming years.
The Diagnostic Biomarkers segment is projected to reach approximately 51.1 USD Billion by 2035, making it a leading segment.
Predictive Biomarkers are expected to reach around 34.2 USD Billion by 2035, while Prognostic Biomarkers are projected at approximately 29.5 USD Billion.
Pharmaceutical Companies are projected to dominate the market with an expected valuation of around 69.0 USD Billion by 2035.
The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) [Center for Devices and Radiological Health, Oncology Center of Excellence], European Medicines Agency (EMA) [Biomarker Qualification Team], National Institutes of Health (NIH) [National Cancer Institute (NCI), National Institute of Neurological Disorders and Stroke (NINDS), National Heart, Lung, and Blood Institute (NHLBI)], National Center for Biotechnology Information (NCBI/PubMed), ClinicalTrials.gov, World Health Organization (WHO) [International Agency for Research on Cancer (IARC)], Centers for Disease Control and Prevention (CDC) [National Center for Health Statistics], Centers for Medicare & Medicaid Services (CMS) [Molecular Diagnostics Services Guidelines], European Commission Joint Research Centre (JRC), Pharmaceuticals and Medical Devices Agency (PMDA) Japan, National Medical Products Administration (NMPA) China, European Federation of Pharmaceutical Industries and Associations (EFPIA), Biotechnology Innovation Organization (BIO), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), and national cancer registries from key markets. These sources were used to collect epidemiological statistics, regulatory approval data for companion diagnostics, clinical validation studies, biomarker qualification pathways, procedural volume data for molecular testing, and competitive landscape analysis for genomic biomarkers, proteomic assays, metabolomic panels, and imaging biomarkers.
Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources consist of CEOs, VPs of Research & Development, Chief Scientific Officers (CSOs), regulatory affairs heads, and commercial directors from in-vitro diagnostic (IVD) manufacturers, life sciences companies, next-generation sequencing (NGS) platform developers, and analytical instrument OEMs. Demand-side sources included procurement leads from academic medical centers, hospital laboratories, reference laboratories, contract research organizations (CROs), and pharmaceutical R&D units, as well as board-certified pathologists, medical oncologists, neurologists, cardiologists, clinical laboratory directors, and chief of molecular diagnostics. The primary research validated market segmentation across disease indications, confirmed companion diagnostic pipeline timelines, and gathered insights on the clinical adoption patterns of liquid biopsy assays, reimbursement dynamics for multiplex biomarker testing, and laboratory workflow integration challenges.
Primary Respondent Breakdown:
• By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)
• By Region: North America (38%), Europe (25%), Asia-Pacific (28%), Rest of World (9%)
Global market valuation was derived through revenue mapping and test volume analysis across clinical diagnostics and pharmaceutical R&D applications. The methodology included:
• Identification of 50+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America, spanning molecular diagnostics, immunoassay platforms, mass spectrometry systems, and bioinformatics solutions
• Product mapping across consumables (assay kits, reagents), instruments (PCR systems, NGS platforms, analyzers), and services (test development, bioinformatics, companion diagnostic co-development)
• Segment-wise analysis covering safety biomarkers (renal, hepatic, cardiac toxicity), efficacy biomarkers (prognostic, predictive, pharmacodynamic), and validation biomarkers
• Technology coverage across genomics, proteomics, metabolomics, epigenetics, and lipidomics platforms
• Disease indication mapping across oncology (solid tumors, hematological malignancies), cardiovascular disorders, neurological diseases (Alzheimer's, Parkinson's), and infectious diseases
• Analysis of reported and modeled annual revenues specific to biomarker portfolios and companion diagnostic partnerships
• Coverage of manufacturers representing 75-80% of global market share in 2024
• Extrapolation using bottom-up (test volume × ASP by country/region across clinical labs and pharma R&D) and top-down (manufacturer revenue validation, service provider contract values) approaches to derive segment-specific valuations across diagnostic applications, drug discovery & development, and personalized medicine segments
Kindly complete the form below to receive a free sample of this Report
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
“Thank you, this will be very helpful for OQS.”
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”
